Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for adults with KRAS G12C-mutated metastatic colorectal cancer (CRC ...

Scientists identified a link between colorectal cancer and a toxin in the gut. Eating more fiber may help reduce your risk.

although Amgen has also reported positive pivotal trial results in KRAS G12C-mutated colorectal cancer for Lumakras in combination with its own EGFR drug Vectibix (panitumumab). The CRC approval ...

Colorectal cancer (CRC) remains one of the most prevalent and deadly cancers worldwide, with rising incidence linked to dietary and lifestyle changes.

The FDA granted accelerated approval to adagrasib (Krazati) for KRAS G12C-mutated colorectal cancer (CRC), which ... paired the KRAS inhibitor sotorasib (Lumakras) and the EGFR inhibitor ...

The first patient has received TCMCB07 in a phase 2 trial to prevent weight loss in patients with metastatic colorectal cancer undergoing chemotherapy. KSQ-004EX is being evaluated in solid tumors ...

Amgen’s Lumakras and Bristol Myers Squibb’s ... A Phase 1 test is underway evaluating BBO-10203 in advanced cases of breast ...

Lumakras is designed for advanced or metastatic non-small cell lung cancer. It is effective against tumors with KRAS G12C mutation, which occurs in 30% of lung, colon, pancreas and thyroid cancers.